Why can’t Dasatinib be reimbursed?

Dasatinib (Dasatinib) is a targeted drug commonly used to treat chronic myelogenous leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL). It has high efficacy and is recommended by many countries as one of the first-choice drugs for the treatment of leukemia. After Dasatinib was launched in the country, it has also been included in the national Class B medical insurance. However, the reasons why it cannot be reimbursed may involve the following aspects:

First, medical insurance reimbursement policies vary from country to country and region to region. In some countries, especially developed countries, dasatinib may have been included in health insurance plans, so patients can receive partial or full reimbursement of the cost of the drug if they meet certain conditions. However, in some developing countries or areas with limited medical resources, reimbursement may become a difficult task due to the high price of dasatinib. In addition, even if the drug is covered by a health insurance plan, there may be an individual out-of-pocket limit or pro-rata payment requirements.

Secondly, whether dasatinib can be reimbursed also depends on the patient's specific situation. For example, some health plans may only cover patients with certain types of leukemia, or may reimburse dasatinib only if it is considered the standard of care for that type of leukemia. In addition, the patient's financial status may also affect whether he or she can obtain medical insurance reimbursement.

These are just some of the possible causes and may vary by region and individual circumstances. The original research price of dasatinib currently on the market in China is more than RMB 10,000. If patients have questions about the medical insurance reimbursement of dasatinib, they can consult local hospitals or medical insurance bureaus to learn whether specific policies and personal circumstances meet the reimbursement requirements.